Generic Name: alpelisib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Experimental Code: BYL719
Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.
Piqray inhibits phosphatidylinositol-3-kinase (PI3K), an enzyme that is part of signaling pathways that play a role in cell growth and metabolism. The Phase III SOLAR-1 study showed that Piqray plus Faslodex (fulvestrant) prolonged progression-free survival by five months. Piqray was first approved in 2019.
Dosing Info: Piqray is taken as two tablets once daily with food.
Common side effects of Piqray include diarrhea, nausea, weight loss, rash, fatigue, mouth sores, decreased appetite, hair loss, low white blood cell count and various laboratory abnormalities including high blood sugar and elevated liver enzymes. More serious side effects may include severe hypersensitivity reactions, severe skin rash, severe diarrhea, serious hyperglycemia and lung inflammation. Piqray can cause fetal harm if used during pregnancy.
Last Reviewed: May 24, 2019